Equities

YiChang HEC ChangJiang Pharmaceutical Co Ltd

YiChang HEC ChangJiang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)12.80
  • Today's Change0.300 / 2.40%
  • Shares traded1.99m
  • 1 Year change+82.86%
  • Beta1.0086
Data delayed at least 15 minutes, as of Apr 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.

  • Revenue in HKD (TTM)6.80bn
  • Net income in HKD2.15bn
  • Incorporated2001
  • Employees4.62k
  • Location
    YiChang HEC ChangJiang Pharmaceutical Co LtdNo. 38, Binjiang Road, Yidu CityDONGGUAN 443300ChinaCHN
  • Phone+86 76 981768866
  • Fax+86 76 981768866
  • Websitehttp://www.hec-changjiang.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
1558:HKG since
announced
Transaction
value
Dongguan Hec Taigen Biopharmaceuticals Co LtdAnnounced22 Nov 202322 Nov 2023Announced52.02%4.98m
Data delayed at least 15 minutes, as of Apr 26 2024 09:08 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lepu Biopharma Co Ltd243.56m-23.88m7.80bn429.00--8.0597.3532.02-0.0144-0.01440.14680.58420.09171.061.62567,748.90-1.23---1.91--87.45---13.45--0.72010.13920.4549--1,347.16--96.79------
Everest Medicines Ltd136.11m-912.71m7.81bn432.00--1.43--57.40-2.92-2.920.434816.820.02032.254.57315,068.20-13.63-30.52-15.06-33.1472.67---670.57-5,745.258.29--0.0979--884.46---241.50--4.65--
Cansino Biologics Inc373.08m-1.60bn8.39bn1.49k--0.7969--22.49-6.49-6.491.5123.040.03322.370.4626249,717.90-18.93-4.27-26.69-5.60-253.78---569.97-27.721.86--0.3381---66.52213.94-63.04--30.60--
Shanghai Henlius Biotech Inc5.83bn590.15m8.88bn3.64k15.093.759.081.521.081.0810.684.360.57311.959.101,603,220.005.80-8.5912.47-14.1472.6471.7710.12-27.370.37866.480.6512--67.82273.51178.53--49.14--
InnoCare Pharma Ltd798.22m-682.28m8.90bn1.07k--1.00--11.16-0.4045-0.40450.4734.380.0731.393.39---6.38-13.41-8.08-15.3682.6185.99-87.42-172.164.13--0.1582--18.09240.3628.80------
Keymed Biosciences Inc382.71m-388.40m9.78bn897.00--3.03--25.55-1.49-1.491.4511.540.09060.731426.14426,657.60-9.16---10.05--89.59---101.04--9.18--0.123--253.87---16.63------
AIM Vaccine Co Ltd1.28bn-1.41bn9.91bn1.62k--2.52--7.72-1.16-1.161.063.25------790,292.90--------75.88---164.24--0.7583-11.540.3158---6.06---307.07------
Luye Pharma Group Ltd6.64bn575.65m10.16bn5.01k17.560.70767.571.530.15380.15381.783.820.2472.423.24--2.172.803.564.4568.4470.538.7810.391.212.680.3837--2.703.50-11.94-16.39----
Yichang Hec Changjiang Pharmactcl Co Ltd6.80bn2.15bn11.00bn4.62k5.111.284.531.622.452.457.739.750.51113.624.001,473,212.0015.078.0324.4611.8179.2179.9729.4820.801.309.320.2475--68.0820.182,501.2416.15----
SciClone Pharmaceuticals (Holdings) Ltd3.41bn1.21bn11.29bn1.05k9.663.1914.753.311.861.865.245.630.75853.563.833,248,230.0026.9727.0933.3436.3274.6776.0635.5535.434.5027.950.01--14.7617.5031.1615.96----
Zai Lab Ltd2.09bn-2.62bn12.54bn2.18k--1.97--6.00-2.71-2.712.166.410.23642.515.38---29.66-37.72-34.97-42.7264.0864.75-125.46-282.444.41--0.00--24.03360.0324.51---3.45--
Simcere Pharmaceutical Group Ltd7.14bn772.53m13.68bn7.03k18.081.7612.361.910.28980.28982.742.980.61063.532.651,016,341.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
SSY Group Ltd6.46bn1.32bn14.07bn5.60k10.712.038.052.180.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
Data as of Apr 26 2024. Currency figures normalised to YiChang HEC ChangJiang Pharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

4.42%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 202415.58m2.38%
Dimensional Fund Advisors LPas of 04 Apr 20245.78m0.88%
Norges Bank Investment Managementas of 31 Dec 20232.98m0.46%
BlackRock Fund Advisorsas of 04 Apr 20241.33m0.20%
BlackRock Advisors (UK) Ltd.as of 02 Apr 2024846.40k0.13%
American Century Investment Management, Inc.as of 04 Apr 2024737.40k0.11%
Schroder Investment Management North America, Inc.as of 28 Feb 2021449.60k0.07%
SSgA Funds Management, Inc.as of 04 Apr 2024424.60k0.07%
Generation Investment Management LLPas of 31 Dec 2019380.80k0.06%
AXA Investment Managers Asia (Singapore) Ltd.as of 29 Feb 2024376.40k0.06%
More ▼
Data from 31 Dec 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.